The current read
REGAL is a real survival win, but the price outruns the patients. We back-calculate a 95% confidence interval of about 0.36–0.96 around the 0.59 hazard ratio, close to no effect at the upper end, and SELLAS has not disclosed the analysis set, the survival curves or the transplant counts.
- On our numbers SELLAS is worth $5.48 a share on self-launch economics and about $9.20 to an acquirer, against a $17.95 close on 18 November and the $13.00 offering price. At our base course, $17.95 needs ~1,540 US patients treated a year on acquirer economics, more than twice our ~640 base case. Only a longer, pricier course (~1,110 patients) fits under our ~1,280 eligible-patient ceiling, and only at ~87% of eligible patients. Acquirer value cleared $17.95 in 0.3% of 100,000 simulated scenarios.
- We are cautious, not short. Short interest was ~28% before the readout, two SLS009 readouts land within weeks, and a buyer could use more generous inputs than ours. This is research, not a call on SLS.